يعرض 1 - 10 نتائج من 26 نتيجة بحث عن '"Baltzer, Lorraine"', وقت الاستعلام: 1.43s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المساهمون: Department of Otolaryngology–Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, Department of Otolaryngology – Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, Stanford Cancer Center, Stanford University Medical Center, Stanford, California, Lahey Clinic Medical Center, Burlington, Massachusetts, Department of Otolaryngology–Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, University of Kentucky, Lexington, Kentucky, University of Pennsylvania, Philadelphia, Pennsylvania, Department of Otolaryngology–Head and Neck Surgery, University of Alabama Hospital, Birmingham, Alabama, Department of Otolaryngology–Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, Department of Medical Affairs, IRX Therapeutics, New York, New York, Department of Clinical Operations, IRX Therapeutics, New York, New York, Department of Scientific Affairs, IRX Therapeutics, New York, New York

    وصف الملف: application/pdf

    العلاقة: Wolf, Gregory T.; Fee, Willard E.; Dolan, Robert W.; Moyer, Jeffrey S.; Kaplan, Michael J.; Spring, Paul M.; Suen, James; Kenady, Daniel E.; Newman, Jason G.; Carroll, William R.; Gillespie, M. Boyd; Freeman, Scott M.; Baltzer, Lorraine; Kirkley, Terry D.; Brandwein, Harvey J.; Hadden, John W. (2011). "Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer ." Head & Neck 33(12): 1666-1674.; https://hdl.handle.net/2027.42/88112Test; Head & Neck; Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74 – 108.; Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71 – 96.; Wu AA, Niparko KJ, Pai SI. Immunotherapy for head and neck cancer. J Biomed Sci 2008; 15: 275 – 289.; Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review. SEER web site 2008. http://www.seer.cancer.govTest. Accessed May 30, 2008.; Alhamarneh O, Amarnath SM, Stafford ND, Greenman J. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 2008; 30: 251 – 261.; Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005; 24: 95 – 105.; Leibowitz MS, Nayak JV, Ferris RL. Head and neck cancer immunotherapy: clinical evaluation. Curr Oncol Rep 2008; 10: 162 – 169.; Patt BS, Close LG, Vuitch F. Prognostic significance of sinus histiocytosis in metastatic laryngeal cancer. Laryngoscope 1993; 103: 498 – 502.; Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371: 1695 – 1709.; Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007; 25: 862 – 868.; Hadden JW, Saha A, Sosa M, Hadden EM. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T‐lymphocyte responses of hydrocortisone‐treated aged mice. Int J Immunopharmacol 1995; 17: 821 – 828.; Egan JE, Quadrini KJ, Santiago‐Schwarz F, Hadden JW, Brandwein HJ, Signorelli KL. IRX‐2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 2007; 30: 624 – 633.; Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low‐dose cyclophosphamide. Blood 2005; 105: 2862 – 2868.; Lönnroth C, Andersson M, Arvidsson A, et al. Preoperative treatment with a non‐steroidal anti‐inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008; 8: 5.; Lieb J. Antidepressants, prostaglandins and the prevention and treatment of cancer. Med Hypotheses 2007; 69: 684 – 689.; Fraker PJ, King LE. Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr 2004; 24: 277 – 298.; Prasad AS, Beck FW, Doerr TD, et al. Nutritional and zinc status of head and neck cancer patients: an interpretive review. J Am Coll Nutr 1998; 17: 409 – 418.; Freeman SM, Barrera JL, Kenady DE, et al. A phase 1 safety study of an IRX‐2 regimen in patients with squamous cell carcinoma of the head and neck. Am J Clin Oncol 2010. [Epub ahead of print]; Hamada I, Kato M, Okada K. Multi‐cytokine therapy for advanced renal cell carcinoma: determination of the minimal effective dose. Anticancer Res 2002; 22: 2429 – 2436.; Abdel‐Wahab M, El‐Shennawy F, Agha S, et al. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin‐2 (IL‐2). Hepatogastroenterology 1999; 46 Suppl 1: 1293 – 1296.; Vlock DR, Snyderman CH, Johnson JT, et al. Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin‐2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol 1994; 15: 134 – 139.; Pulley MS, Nagendran V, Edwards JM, Dumonde DC. Intravenous, intralesional and endolymphatic administration of lymphokines in human cancer. Lymphokine Res 1986; 5 Suppl 1: S157 – S163.; Zhang L, Conejo‐Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203 – 213.; Haanen JB, Baars A, Gomez R, et al. Melanoma‐specific tumor‐infiltrating lymphocytes but not circulating melanoma‐specific T cells may predict survival in resected advanced‐stage melanoma patients. Cancer Immunol Immunother 2006; 55: 451 – 458.; Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T‐lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis. Arch Otolaryngol Head Neck Surg 1987; 113: 1200 – 1206.; Czystowska M, Han J, Szczepanski MJ, et al. IRX‐2, a novel immunotherapeutic, protects human T cells from tumor‐induced cell death. Cell Death Differ 2009; 16: 708 – 718.; Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009; 2009: 346345.

  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    كتاب
  10. 10
    دورية أكاديمية